Mechanisms of resistance to cisplatin - PubMed (original) (raw)
Review
Mechanisms of resistance to cisplatin
M Kartalou et al. Mutat Res. 2001.
Abstract
The use of cisplatin in cancer chemotherapy is limited by acquired or intrinsic resistance of cells to the drug. Cisplatin enters the cells and its chloride ligands are replaced by water, forming aquated species that react with nucleophilic sites in cellular macromolecules. The presence of the cisplatin adducts in DNA is thought to trigger cell cycle arrest and apoptosis. Knowledge of the mechanism of action of cisplatin has improved our understanding of resistance. Decreased intracellular concentration due to decreased drug uptake, increased reflux or increased inactivation by sulfhydryl molecules such as glutathione can cause resistance to cisplatin. Increased excision of the adducts from DNA by repair pathways or increased lesion bypass can also result in resistance. Finally, altered expression of regulatory proteins involved in signal transduction pathways that control the apoptotic pathway can also affect sensitivity to the drug. An improved understanding of the mechanisms of resistance operative in vivo has identified targets for intervention and may increase the utility of cisplatin for the treatment of cancer.
Similar articles
- Recognition of cisplatin adducts by cellular proteins.
Kartalou M, Essigmann JM. Kartalou M, et al. Mutat Res. 2001 Jul 1;478(1-2):1-21. doi: 10.1016/s0027-5107(01)00142-7. Mutat Res. 2001. PMID: 11406166 Review. - Cisplatin resistance and oncogenes--a review.
Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ. Dempke W, et al. Anticancer Drugs. 2000 Apr;11(4):225-36. doi: 10.1097/00001813-200004000-00001. Anticancer Drugs. 2000. PMID: 10898536 Review. - Cisplatin.
Trimmer EE, Essigmann JM. Trimmer EE, et al. Essays Biochem. 1999;34:191-211. doi: 10.1042/bse0340191. Essays Biochem. 1999. PMID: 10730196 Review. - Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance.
Lanzi C, Perego P, Supino R, Romanelli S, Pensa T, Carenini N, Viano I, Colangelo D, Leone R, Apostoli P, Cassinelli G, Gambetta RA, Zunino F. Lanzi C, et al. Biochem Pharmacol. 1998 Apr 15;55(8):1247-54. doi: 10.1016/s0006-2952(97)00599-6. Biochem Pharmacol. 1998. PMID: 9719480 - Cisplatin.
Reed E. Reed E. Cancer Chemother Biol Response Modif. 1999;18:144-51. Cancer Chemother Biol Response Modif. 1999. PMID: 10800481 Review. No abstract available.
Cited by
- Acquired resistance of leukemic cells to AraC is associated with the upregulation of aldehyde dehydrogenase 1 family member A2.
Kawasoe M, Yamamoto Y, Okawa K, Funato T, Takeda M, Hara T, Tsurumi H, Moriwaki H, Arioka Y, Takemura M, Matsunami H, Markey SP, Saito K. Kawasoe M, et al. Exp Hematol. 2013 Jul;41(7):597-603.e2. doi: 10.1016/j.exphem.2013.03.004. Epub 2013 Mar 15. Exp Hematol. 2013. PMID: 23507523 Free PMC article. - Strategies to reduce the risk of platinum containing antineoplastic drug-induced ototoxicity.
Mukherjea D, Dhukhwa A, Sapra A, Bhandari P, Woolford K, Franke J, Ramkumar V, Rybak L. Mukherjea D, et al. Expert Opin Drug Metab Toxicol. 2020 Oct;16(10):965-982. doi: 10.1080/17425255.2020.1806235. Epub 2020 Sep 29. Expert Opin Drug Metab Toxicol. 2020. PMID: 32757852 Free PMC article. Review. - Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: a retrospective evaluation.
Astolfi L, Ghiselli S, Guaran V, Chicca M, Simoni E, Olivetto E, Lelli G, Martini A. Astolfi L, et al. Oncol Rep. 2013 Apr;29(4):1285-92. doi: 10.3892/or.2013.2279. Epub 2013 Feb 6. Oncol Rep. 2013. PMID: 23404427 Free PMC article. - EGFR Targeted Theranostic Nanoemulsion for Image-Guided Ovarian Cancer Therapy.
Ganta S, Singh A, Kulkarni P, Keeler AW, Piroyan A, Sawant RR, Patel NR, Davis B, Ferris C, O'Neal S, Zamboni W, Amiji MM, Coleman TP. Ganta S, et al. Pharm Res. 2015 Aug;32(8):2753-63. doi: 10.1007/s11095-015-1660-z. Epub 2015 Mar 4. Pharm Res. 2015. PMID: 25732960 Free PMC article. - Synthesis and Characterisation of Platinum(II) Diaminocyclohexane Complexes with Pyridine Derivatives as Anticancer Agents.
McGhie BS, Sakoff J, Gilbert J, Gordon CP, Aldrich-Wright JR. McGhie BS, et al. Int J Mol Sci. 2023 Dec 5;24(24):17150. doi: 10.3390/ijms242417150. Int J Mol Sci. 2023. PMID: 38138979 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources